SynthesisCanadian journal of gastroenterology = Journal canadien de gastroenterologie2009
Prevention of Clostridium difficile infection with Saccharomyces boulardii: a systematic review.
Synthesis in Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A practical guide for probiotics applied to the case of antibiotic-associated diarrhea in The Netherlands.BMC gastroenterology · 2018Guideline
- Efficacy and safety of Saccharomyces boulardii as adjunct therapy with Vancomycin in treating Clostridioides difficile infection: A randomized controlled trial.Scientific reports · 2025Trial
- Article
- Central Line-Related Bloodstream Infection byMicroorganisms · 2025Article
- Emerging microbiome-directed therapies in inflammatory bowel disease: beyond diet modification and FMT.Seminars in immunopathology · 2025Review
- Encapsulation of Saccharomyces boulardii into sugar pellets coated with an enteric polymer.World journal of microbiology & biotechnology · 2025Article
- Mitigating Diarrhoea-Related Inflammation in Frail Older Adults with Postbiotic-Enhanced Oral Rehydration Solution: Insights from a Randomised, Double-Blind, Placebo-Controlled Study.Geriatrics (Basel, Switzerland) · 2025Article
- Probiotics and human health: biological activities, nutritional aspects, immunomodulatory properties, applications, and future perspectives - a comprehensive review.Frontiers in immunology · 2025Review
- Effectiveness of Saccharomyces boulardii CNCM I-745 in Adult Indian Patients with Diarrhoea: A Real-world, Multicentre, Retrospective, Comparative Study.Drugs - real world outcomes · 2024Article
- Anti-Cariogenic Effects ofPharmaceutics · 2024Article
- Review
- Role of probiotics in preventingFrontiers in medicine · 2023Review
- Effect of Probiotics on Host-Microbiota in Bacterial Infections.Pathogens (Basel, Switzerland) · 2022Review
- Application of Probiotic Yeasts onJournal of fungi (Basel, Switzerland) · 2020Review
- Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases.Current microbiology · 2020Review
- Trehalose Protects the Probiotic YeastJournal of microbiology and biotechnology · 2020Article
- Impact of microbiome-based interventions on gastrointestinal pathogen colonization in the intensive care unit.Therapeutic advances in gastroenterology · 2020Review
- Cross-Domain and Viral Interactions in the Microbiome.Microbiology and molecular biology reviews : MMBR · 2019Review
- A Mutation inApplied and environmental microbiology · 2018Article
- Learning from other diseases: protection and pathology in chronic fungal infections.Seminars in immunopathology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClostridium difficile is a major cause of antibiotic-associated diarrhea within the hospital setting. The yeast Saccharomyces boulardii has been found to have some effect in reducing the risk of C difficile infection (CDI); however, its role in preventive therapy has yet to be firmly established.
objectiveTo review the effectiveness of S boulardii in the prevention of primary and recurrent CDI. Benefit was defined as a reduction of diarrhea associated with C difficile. Risk was defined as any adverse effects of S boulardii.
methodsA literature search in MEDLINE, EMBASE, CINAHL and the Cochrane Library was performed. Included studies were English language, randomized, double-blind placebo controlled trials evaluating S boulardii in CDI prevention.
resultsFour studies were reviewed. Two studies investigated the prevention of recurrence in populations that were experiencing CDI at baseline. One trial showed a reduction of relapses in patients experiencing recurrent CDI (RR=0.53; P<0.05). The other demonstrated a trend toward reduction of CDI relapse in the recurrent treatment group of patients receiving high-dose vancomycin (RR=0.33; P=0.05). Two other studies examined primary prevention of CDI in populations that had been recently prescribed antibiotics. These studies lacked the power to detect statistically significant differences. Patients on treatment experienced increased risk for thirst and constipation.
conclusionS boulardii seems to be well tolerated and may be effective for secondary prevention in some specific patient populations with particular concurrent antibiotic treatment. Its role in primary prevention is poorly defined and more research is required before changes in practice are recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.